Boston Scientific to acquire the Interventional Division of Bayer AG
According to a Boston Scientific Corp. press release from May 15, 2014, the company has entered into a definitive agreement to acquire the Interventional Division of Bayer AG for $415 million. The transaction is expected to close in the second half of 2014. The press release notes that “[i]n 2013, Bayer Interventional generated sales of approximately $120 million.”
Included in the transaction are Bayer Interventional technologies designed to treat coronary and peripheral vascular disease. These technologies include “the AngioJet® Thrombectomy System and the Fetch® 2 Aspiration Catheter, which use endovascular techniques to remove blood clots from blocked arteries and veins, and the JetStream® Atherectomy System, a minimally invasive device used to remove plaque from diseased peripheral arteries.”
According to the press release, “[t]he acquisition is expected to improve Boston Scientific’s access to a number of attractive segments in the peripheral space, including the growing atherectomy and thrombectomy categories.”
Jeff Mirviss, president, Peripheral Interventions, Boston Scientific describes the effects of the transaction saying:
The addition of Bayer Interventional will expand our commercial footprint and enhance our ability to provide physicians and healthcare systems with a complete portfolio of solutions to treat challenging vascular conditions, . . . We believe this acquisition will accelerate the growth of our Peripheral Interventions business and strengthen our position as a global leader in peripheral therapies.
Indiana University Research and Technology Corporation Files Patent Infringement Lawsuit
Indiana University Research & Technology Corporation (IURTC) filed a lawsuit against AngioDynamics, Inc. alleging infringement of U.S. Patent No. 6,719,717 (“the ‘717 Patent”). The lawsuit was filed on December 18, 2013 in the Southern District of Indiana. The ‘717 Patent is entitled “Thrombectomy Treatment System and Method.”
The ‘717 Patent states that it “relates generally to a thrombectomy treatment system and method, and more particularly to a percutaneous thrombectomy system and method providing reinfusion of treated blood that is free of blood clots.” Figure 1 from the ‘717 Patent is shown below:
The complaint alleges that AngioDynamics infringes the ‘717 Patent by “having made, importing into the United States, and/or using, selling, and/or offering for sale in the United States,” its AngioVac Cannula and Circuit products.
According to its website, IURTC is a “not-for-profit agency that assists IU faculty and researchers in realizing the commercial potential of their discoveries.” According to its website, AngioDynamics is headquartered in Albany, New York, and has products that include radiofrequency ablation and NanoKnife® systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products, venous products and targeted renal therapy products.
Share
